Lydia Roy
YOU?
Author Swipe
View article: Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients
Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients Open
In chronic myeloid leukemia (CML), the role of immune effectors has been suggested in the achievement of a sustained deep molecular response (DMR) and treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation. A …
View article: Food Insecure College Students Have Worse Health-related Quality of Life Than Their Food Secure Peers
Food Insecure College Students Have Worse Health-related Quality of Life Than Their Food Secure Peers Open
View article: Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study
Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study Open
Accelerated‐phase (AP) or blast‐phase (BP) myeloproliferative neoplasms (MPNs) are associated with dismal prognosis, with non‐curative therapies such as hypomethylating agents (HMAs) considered in patients not eligible for intensive therap…
View article: Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools
Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools Open
Predicting therapeutic failure in patients with chronic phase-chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKI) remains a major challenge for personalized care management. The Sokal and EUTOS long-term surviva…
View article: A molecular signature predicts hematologic evolution in polycythemia vera patients
A molecular signature predicts hematologic evolution in polycythemia vera patients Open
Genetic analyses have been included in scoring systems to improve the prognostic stratification of hematologic malignancies. Until now, molecular risk scores have not been included into the practical management of patients with polycythemi…
View article: The Influence of In Vitro Test Conditions on the Biomechanical Properties of Degenerated Lateral Menisci - A Ring Study
The Influence of In Vitro Test Conditions on the Biomechanical Properties of Degenerated Lateral Menisci - A Ring Study Open
The biomechanical properties of degenerated meniscal tissue are increasingly being studied in the context of osteoarthritis research. Spatial indentation testing using a multiaxial testing machine allows non-destructive characterization of…
View article: Subclonal emergence of polycythemia vera, chronic myelomonocytic leukemia, and chronic myeloid leukemia
Subclonal emergence of polycythemia vera, chronic myelomonocytic leukemia, and chronic myeloid leukemia Open
The present longitudinal study reports a unique patient followed over almost three decades who sequentially developed polycythemia vera, chronic myelomonocytic leukemia, and chronic myeloid leukemia. The patient received successive hydroxy…
View article: Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient
Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient Open
View article: Nilotinib Versus Nilotinib Combined to Pegylated Interferon-Alpha2a as First-Line Therapy in Chronic Phase Chronic Myeloid Leukaemia. Final Results of the National Academic Phase Iii Petals Trial
Nilotinib Versus Nilotinib Combined to Pegylated Interferon-Alpha2a as First-Line Therapy in Chronic Phase Chronic Myeloid Leukaemia. Final Results of the National Academic Phase Iii Petals Trial Open
View article: Clinical outcomes in patients in any phase of <scp>CML</scp> treated with ponatinib in France—Data from the <scp>TOPASE</scp> observational study
Clinical outcomes in patients in any phase of <span>CML</span> treated with ponatinib in France—Data from the <span>TOPASE</span> observational study Open
Summary The TOPASE study was set up to evaluate the outcomes of chronic myeloid leukaemia [CML] patients treated with ponatinib (PON) in a real‐world setting in France. One hundred and twenty CML patients, 105 in chronic phase (CP), 8 in a…
View article: “Give us fresh fruit.” Students’ Perceptions of the School Food Environment Compared to Skin Carotenoid Levels
“Give us fresh fruit.” Students’ Perceptions of the School Food Environment Compared to Skin Carotenoid Levels Open
View article: Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial Open
Correction to: Leukemiahttps://doi.org/10.1038/s41375-024-02145-6 published online 26 January 2024 The information provided in the Figure III legend states: “TFR probability at 6, 12 and 24 months was 62, 55 and 42%respectively”, the figur…
View article: Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs
Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs Open
Not available.
View article: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial Open
View article: Optimisation du bosutinib dans la leucémie myéloïde chronique : recommandations du Fi-LMC (France Intergroupe des leucémies myéloïdes chroniques)
Optimisation du bosutinib dans la leucémie myéloïde chronique : recommandations du Fi-LMC (France Intergroupe des leucémies myéloïdes chroniques) Open
The treatment of chronic myeloid leukemia relies on orally available tyrosine kinase inhibitors targeting the BCR::ABL1 oncoprotein. Bosutinib is a second generation adenosine triphosphate-competitive inhibitor approved for use in frontlin…
View article: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial Open
Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessat…
View article: Supplementary Figure 1 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients
Supplementary Figure 1 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients Open
PDF file - 200KB, The kinase activity of BCR-ABL induces upregulation of ST2 in UT7 cells.
View article: Supplementary Figure 1 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients
Supplementary Figure 1 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients Open
PDF file - 200KB, The kinase activity of BCR-ABL induces upregulation of ST2 in UT7 cells.
View article: Supplementary Figure 2 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients
Supplementary Figure 2 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients Open
PDF file - 192KB, CML-CP CD34(+) cells proliferate in response to IL-33.
View article: Supplementary Figure Legends from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients
Supplementary Figure Legends from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients Open
PDF file - 89KB
View article: Supplementary Figure 3 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients
Supplementary Figure 3 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients Open
PDF file - 118KB, IL-33 does not modulate apoptosis of CD34(+) cells from CML-CP patients.
View article: Data from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients
Data from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients Open
Although it is generally acknowledged that cytokines regulate normal hematopoiesis in an autocrine/paracrine fashion, their possible role in chronic myelogenous leukemia (CML) and resistance to imatinib mesylate treatment remain poorly inv…
View article: Supplementary Figures 1 - 5 from Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
Supplementary Figures 1 - 5 from Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells Open
PDF file - 589K, shS5A, shS5B and shS5A/B differentially affect STAT5 expression in CML and normal stem/progenitor cells (S1); Characteristics of CML cells following addition of the indicated shRNA encoding lentiviral particles (S2); shS5A…
View article: Supplementary Figure Legends from Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
Supplementary Figure Legends from Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells Open
PDF file - 32K
View article: Data from Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
Data from Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells Open
STAT5 fulfills essential roles in hematopoietic stem cell (HSC) self-renewal and chronic myeloid leukemia (CML), a prototypical stem cell malignancy. However, the specific contributions of the two related genes STAT5A and STAT5B have not b…
View article: Supplementary Figures 1 - 5 from Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
Supplementary Figures 1 - 5 from Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells Open
PDF file - 589K, shS5A, shS5B and shS5A/B differentially affect STAT5 expression in CML and normal stem/progenitor cells (S1); Characteristics of CML cells following addition of the indicated shRNA encoding lentiviral particles (S2); shS5A…
View article: Supplementary Figure 5 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients
Supplementary Figure 5 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients Open
PDF file - 154KB, CML-CP CD34(+) cells proliferate in response to IL-33 independently from GM-CSF.
View article: Supplementary Figure 3 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients
Supplementary Figure 3 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients Open
PDF file - 118KB, IL-33 does not modulate apoptosis of CD34(+) cells from CML-CP patients.
View article: Supplementary Figure 4 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients
Supplementary Figure 4 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients Open
PDF file - 145KB, IL-33 is as efficient as SCF in inducing proliferation of CML-CP CD34(+) cells.
View article: Supplementary Figure 7 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients
Supplementary Figure 7 from BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients Open
PDF file - 208KB, Xenotransplant experiments in immunodeficient NOG mice (A); Mouse model of CML-like induced syndrome (B-C).